Price Chart

Profile

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
URL https://www.jazzpharmaceuticals.com
Investor Relations URL http://investor.jazzpharma.com
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 28, 2024
Last Earnings Release Nov. 08, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
URL https://www.jazzpharmaceuticals.com
Investor Relations URL http://investor.jazzpharma.com
HQ State/Province N/A
Sector Healthcare
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 28, 2024
Last Earnings Release Nov. 08, 2023
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A